Cancer: Unraveling the Complexities of Uncontrolled Growth and Metastasis

Dr. Arpita Singh*, Dr. Roghini S[1]

*arpitasingh231@gmail.com, Research Associates

ITM University, Gwalior

[1]Associate Professor

ITM University, Gwalior

Abstract: Cancer is a term encompassing a group of diseases characterized by uncontrolled growth and spread of abnormal cells, presents one of the most complex and challenging medical phenomena. Unlike normal cells, cancer cells grow and divide without control, invading surrounding tissues and metastasizing to distant organs. This review provides an in-depth exploration of the underlying genetic and epigenetic mechanisms driving cancer's uncontrolled proliferation, the factors contributing to mutations, and the process of metastasis. It also delves into the classification of cancer based on cell origin and the unique characteristics of different cancer types. The complexity and heterogeneity of cancer are highlighted, along with the advances in molecular biology, genomics, and personalized medicine that are paving the way for targeted therapies. The review underscores the multifaceted nature of cancer and the interplay between genetics, environment, immunity, and other contributing factors. It serves as a comprehensive guide to understanding the intricacies of cancer, offering insights into ongoing research efforts and future directions in cancer diagnosis, treatment, prevention, and control.

Keywords: *Cancer, Uncontrolled Growth, Metastasis, Genetic Mutations, Epigenetics, Carcinogens, Immune Evasion, Tumor Classification*

Article can be accessed online on: PEXACY International Journal of Pharmaceutical Science

DOI: 10.5281/zenodo.8266559

Corresponding Author- *arpita231@gmail.com

Update: Received on 14/08/2023; Accepted; 19/08/2023, Published on; 20/08/2023

1. Introduction

Cancer is a term used to describe a group of diseases characterized by the uncontrolled growth and spread of abnormal cells. Unlike normal cells, which grow, divide, and die in an orderly fashion, cancer cells continue to

grow and divide without control, often invading surrounding tissues and spreading to other parts of the body (Hanahan & Weinberg, 2011). This uncontrolled growth is driven by genetic mutations and epigenetic changes that disrupt the normal regulatory pathways controlling cell proliferation and apoptosis (Stratton et al., 2009). These mutations can be caused by various factors, including exposure to carcinogens, genetic predisposition, and viral infections (Vogelstein et al., 2013).

Cancer cells often evade the immune system, allowing them to thrive and metastasize to distant organs (Schreiber et al., 2011). The process of metastasis is complex and involves multiple steps, including detachment from the primary tumor, invasion into surrounding tissues, entry into the bloodstream or lymphatic system, and colonization of distant organs (Valastyan & Weinberg, 2011). This ability to spread distinguishes malignant tumors from benign tumors, which do not invade other tissues.

Cancer is not a single disease but a collection of related diseases that can occur in virtually any organ system. The classification of cancer is based on the type of cell from which it originates, such as carcinoma (originating from epithelial cells), sarcoma (from connective tissue cells), leukemia (from blood-forming cells), and so on (Fletcher, 2013). Each type of cancer has unique characteristics, risk factors, and requires specific treatment approaches.

The complexity and heterogeneity of cancer make it a challenging disease to understand, diagnose, and treat. Advances in molecular biology, genomics, and personalized medicine are providing new insights into the underlying mechanisms of cancer and paving the way for more targeted and effective therapies (Garraway & Lander, 2013).

1.1 Cellular Characteristics

Cancer cells exhibit several distinct characteristics that differentiate them from normal cells. These include:

- **Uncontrolled Proliferation:** Cancer cells ignore signals that normally regulate cell growth and division, leading to uncontrolled proliferation (Weinberg, 2013).
- **Avoidance of Apoptosis:** Cancer cells evade programmed cell death (apoptosis), allowing damaged cells to survive and proliferate (Fulda & Debatin, 2006).

- **Angiogenesis:** Cancer cells stimulate the formation of new blood vessels (angiogenesis) to supply nutrients and oxygen, supporting tumor growth (Carmeliet & Jain, 2011).
- **Metastatic Potential:** Some cancer cells acquire the ability to invade surrounding tissues and spread to distant organs, a process known as metastasis (Valastyan & Weinberg, 2011).

2. Classification of Cancer

Cancer is classified based on various criteria, including the cell type from which it originates, its histological appearance, molecular characteristics, and clinical behavior.

2.1 Classification by Tissue of Origin

- **Carcinomas:** Originating from epithelial cells, carcinomas are the most common type of cancer. They include cancers of the breast, lung, prostate, and colon. Carcinomas are further classified into subtypes such as adenocarcinoma (glandular tissue) and squamous cell carcinoma (flat cells) (American Cancer Society, 2021).
- **Sarcomas:** These cancers arise from connective tissues like bone, cartilage, and muscle. Examples include osteosarcoma (bone) and rhabdomyosarcoma (muscle) (Fletcher et al., 2013).
- **Leukemias:** Leukemias are cancers of the bone marrow and blood, characterized by the overproduction of abnormal white blood cells. They are classified into acute and chronic forms, as well as lymphocytic and myeloid types (Armitage & Weisenburger, 1998).
- **Lymphomas:** Lymphomas affect the lymphatic system and are divided into Hodgkin and non-Hodgkin lymphomas, based on specific cellular characteristics (Swerdlow et al., 2016).
- **Central Nervous System Cancers:** These include cancers of the brain and spinal cord, such as gliomas and meningiomas (Louis et al., 2016).

2.2 Molecular Classification

With advances in molecular biology, cancers are increasingly classified based on specific genetic and molecular characteristics. This has led to personalized treatment approaches

targeting specific molecular pathways. For example, breast cancers are classified based on the expression of receptors such as estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) (Perou et al., 2000).

2.3 Grading and Staging

Cancers are also classified based on their grade (degree of differentiation) and stage (extent of spread). Grading assesses how closely cancer cells resemble normal cells, while staging considers the size of the tumor, lymph node involvement, and distant metastasis (Edge et al., 2010).

2. Epidemiology of Cancer

2.1 Global Incidence and Prevalence

Cancer is a leading cause of morbidity and mortality worldwide. The global burden of cancer continues to increase, largely due to the aging population and growth, as well as changes in the prevalence of certain risk factors.

2.1.1 Incidence

In 2020, there were an estimated 19.3 million new cancer cases globally. The most common cancers diagnosed were breast, lung, colorectal, prostate, and stomach cancers (Sung et al., 2021).

2.1.2 Prevalence

The prevalence of cancer refers to the number of people living with cancer at a given time. As of 2020, there were approximately 43.8 million cancer survivors worldwide, reflecting improvements in early detection and treatment (Miller et al., 2019).

2.2 Regional Variations

Cancer incidence and mortality rates vary significantly by region and country, reflecting differences in risk factors, healthcare infrastructure, and access to care.

2.2.1 High-Income Countries

High-income countries generally have higher cancer incidence rates but lower mortality rates, reflecting better access to early detection and advanced treatments. However, they also face challenges related to lifestyle-related risk factors such as obesity and tobacco use (Bray et al., 2018).

2.2.2 Low- and Middle-Income Countries

Low- and middle-income countries face unique challenges, including higher rates of infection-related cancers (e.g., liver and cervical cancers) and limited access to

cancer care. The lack of early detection and treatment often leads to higher mortality rates (Farmer et al., 2010).

2.3 Trends Over Time

Understanding trends in cancer incidence and mortality over time provides insights into the effectiveness of prevention and control measures.

2.3.1 Increasing Incidence

The global incidence of cancer has been increasing, driven by factors such as aging populations, urbanization, and changes in lifestyle behaviors (Wild et al., 2020).

2.3.2 Declining Mortality

In many countries, cancer mortality rates have been declining, reflecting advances in early detection, diagnosis, and treatment. However, disparities exist, and progress has been uneven across different cancer types and populations (Siegel et al., 2020).

2.4 Risk Factors

Cancer risk is influenced by a complex interplay of genetic, environmental, and lifestyle factors.

2.4.1 Genetic Factors

Certain inherited gene mutations significantly increase the risk of specific cancers. For example, BRCA1 and BRCA2 mutations are associated with hereditary breast and ovarian cancers (King et al., 2003).

2.4.2 Environmental and Lifestyle Factors

Exposures to carcinogens such as tobacco smoke, ultraviolet radiation, and certain chemicals contribute to cancer risk. Lifestyle choices such as diet, physical activity, and alcohol consumption also play a role (Anand et al., 2008).

2.5 Public Health Implications

The epidemiology of cancer has significant public health implications, informing prevention, screening, and treatment strategies.

2.5.1 Prevention Strategies

Understanding the risk factors for cancer allows for targeted prevention strategies, such as tobacco control, vaccination against cancer-causing infections (e.g., HPV), and promoting healthy lifestyles (Colditz & Wei, 2012).

2.5.2 Screening and Early Detection

Early detection through screening can reduce mortality for certain cancers, such as breast, colorectal, and cervical cancers. Effective screening programs require careful consideration of benefits, risks, and resource allocation (Myers et al., 2015).

2.5.3 Health Disparities

Cancer incidence and outcomes vary by race, ethnicity, socioeconomic status, and geography. Addressing these disparities requires targeted interventions and equitable access to care (DeSantis et al., 2019).

3. Etiology of Cancer

3.1 Genetic Factors

Genetic factors play a crucial role in the development of cancer. Both inherited and acquired genetic mutations can contribute to cancer risk.

3.1.1 Inherited Genetic Mutations

Some individuals inherit mutations that increase their risk of developing specific cancers. For example, mutations in the BRCA1 and BRCA2 genes are associated with hereditary breast and ovarian cancers (King et al., 2003).

3.1.2 Somatic Mutations

Somatic mutations are changes in DNA that occur in individual cells during a person's lifetime. These mutations can result from exposure to carcinogens or occur spontaneously. They can lead to uncontrolled cell growth and the development of tumors (Stratton et al., 2009).

3.1.3 Oncogenes and Tumor Suppressor Genes

Oncogenes are genes that promote cell growth, while tumor suppressor genes inhibit growth. Mutations that activate oncogenes or inactivate tumor suppressor genes can lead to cancer (Vogelstein & Kinzler, 2004).

3.2 Environmental Factors

Environmental exposures can contribute to cancer risk by causing DNA damage and other cellular changes.

3.2.1 Tobacco Smoke

Tobacco smoke is a well-known carcinogen, responsible for approximately 22% of cancer deaths worldwide. It is strongly associated with lung, throat, and bladder cancers (Doll & Peto, 1981).

3.2.2 Ultraviolet Radiation

Exposure to ultraviolet (UV) radiation from the sun or tanning beds can cause skin cancer, including melanoma, basal cell carcinoma, and squamous cell carcinoma (Armstrong & Kricker, 2001).

3.2.3 Occupational Exposures

Certain occupations expose individuals to carcinogens, such as asbestos (mesothelioma), benzene (leukemia), and arsenic (skin and lung cancers) (Driscoll et al., 2005).

3.3 Lifestyle Factors

Lifestyle choices, including diet, physical activity, and alcohol consumption, can influence cancer risk.

3.3.1 Diet

Dietary factors, such as high consumption of red and processed meats, low intake of fruits and vegetables, and obesity, are associated with increased risk of colorectal and other cancers (World Cancer Research Fund, 2018).

3.3.2 Physical Activity

Regular physical activity is associated with a reduced risk of breast, colon, and endometrial cancers. It may influence cancer risk through effects on hormones, immune function, and metabolism (Friedenreich et al., 2016).

3.3.3 Alcohol Consumption

Alcohol consumption is a risk factor for several cancers, including liver, breast, and esophageal cancers. The risk increases with the amount of alcohol consumed (Bagnardi et al., 2015).

3.4 Infectious Agents

Certain infections can lead to cancer by causing chronic inflammation, suppressing the immune system, or directly affecting the DNA of host cells.

3.4.1 Human Papillomavirus (HPV)

HPV is a leading cause of cervical cancer and is also associated with other anogenital and head and neck cancers (Bosch et al., 2008).

3.4.2 Hepatitis B and C Viruses

Chronic infections with hepatitis B and C viruses can lead to liver cancer (El-Serag, 2012).

3.4.3 Helicobacter pylori

Infection with *Helicobacter pylori* is associated with gastric cancer and gastric

mucosa-associated lymphoid tissue (MALT) lymphoma (Uemura et al., 2001).

3.5 Interactions Between Factors

The etiology of cancer is multifactorial, and interactions between genetic, environmental, and lifestyle factors can influence individual risk. For example, individuals with a genetic predisposition to melanoma may have an increased risk if they also have excessive sun exposure (Berwick et al., 2006).

4. Diagnosis and Screening of Cancer

4.1 Diagnostic Methods

Cancer diagnosis involves a combination of clinical examination, imaging studies, laboratory tests, and pathological evaluation.

4.1.1 Clinical Examination

A thorough clinical examination may reveal signs and symptoms suggestive of cancer, such as lumps, changes in skin appearance, or unexplained weight loss (Barton et al., 2014).

4.1.2 Imaging Studies

Imaging modalities such as X-rays, CT scans, MRI, and PET scans provide detailed images of internal structures, aiding in tumor detection, localization, and staging (Hricak et al., 2010).

4.1.3 Laboratory Tests

Blood and other body fluid tests can provide clues to cancer, such as abnormal levels of certain proteins or tumor markers (Duffy, 2001).

4.1.4 Pathological Evaluation

Biopsy and histopathological examination of tissue samples are essential for definitive cancer diagnosis, determining the type, grade, and molecular characteristics of the tumor (Oberman, 1998).

4.2 Screening Methods

Cancer screening aims to detect cancer at an early stage when treatment is more likely to be successful.

4.2.1 Mammography

Mammography is used to screen for breast cancer, allowing for early detection of abnormalities before they become palpable (Tabár et al., 2011).

4.2.2 Colonoscopy

Colonoscopy is a screening method for colorectal cancer, enabling visualization and removal of precancerous polyps (Winawer et al., 1993).

4.2.3 Pap Smear

The Pap smear is used to screen for cervical cancer by detecting precancerous changes in cervical cells (Saslow et al., 2012).

4.2.4 Prostate-Specific Antigen (PSA) Testing

PSA testing is used to screen for prostate cancer, although its use is controversial due to potential overdiagnosis and overtreatment (Moyer, 2012).

4.3 Challenges and Ethical Considerations

Cancer diagnosis and screening present several challenges and ethical considerations.

4.3.1 Sensitivity and Specificity

The accuracy of diagnostic and screening tests, including their sensitivity (ability to detect cancer) and specificity (ability to exclude non-cancer), is crucial for effective cancer management (Pepe et al., 2001).

4.3.2 Overdiagnosis and Overtreatment

Some screening methods may lead to overdiagnosis (detection of cancers that would not cause symptoms) and overtreatment (unnecessary treatment of indolent tumors), raising ethical concerns (Welch & Black, 2010).

4.3.3 Access and Disparities

Access to advanced diagnostic and screening technologies may vary by region, socioeconomic status, and healthcare system, leading to disparities in cancer outcomes (Soneji et al., 2014).

4.3.4 Informed Consent

Informed consent and shared decision-making are essential in cancer screening, ensuring that individuals understand the potential benefits, risks, and uncertainties (Gigerenzer et al., 2010).

5. Treatment of Cancer

5.1 Surgical Treatment

Surgical removal of tumors is a cornerstone of cancer treatment, particularly for solid tumors.

5.1.1 Curative Surgery

Curative surgery aims to remove the entire tumor along with surrounding margins to achieve a cure. It is often used in early-stage cancers (van der Wal et al., 2015).

5.1.2 Palliative Surgery

Palliative surgery is performed to relieve symptoms and improve quality of life in advanced or metastatic cancers (Mercadante et al., 2013).

5.1.3 Minimally Invasive Surgery

Minimally invasive techniques, such as laparoscopy and robotic-assisted surgery, offer potential benefits in terms of reduced morbidity and recovery time (Suda et al., 2015).

5.2 Radiation Therapy

Radiation therapy uses high-energy radiation to kill or damage cancer cells.

5.2.1 External Beam Radiation

External beam radiation delivers targeted radiation from outside the body, commonly used in various cancers such as breast, prostate, and lung cancers (Baskar et al., 2012).

5.2.2 Brachytherapy

Brachytherapy involves placing radioactive sources directly inside or near the tumor, often used in prostate, cervical, and breast cancers (Hoskin et al., 2014).

5.2.3 Radiosensitizers

Radiosensitizers are drugs that enhance the effects of radiation therapy, improving tumor control (Choudhury et al., 2016).

5.3 Chemotherapy

Chemotherapy uses drugs to kill or inhibit the growth of cancer cells.

5.3.1 Cytotoxic Chemotherapy

Cytotoxic agents target rapidly dividing cells, affecting both cancerous and normal cells, leading to side effects (Chabner & Roberts, 2005).

5.3.2 Targeted Therapy

Targeted therapies act on specific molecular targets in cancer cells, offering more precise treatment with potentially fewer side effects (Sawyers, 2004).

5.3.3 Neoadjuvant and Adjuvant Chemotherapy

Neoadjuvant chemotherapy is given before surgery to shrink tumors, while adjuvant chemotherapy is given after surgery to eliminate residual cancer cells (Kaufmann et al., 2007).

5.4 Immunotherapy

Immunotherapy harnesses the immune system to fight cancer.

5.4.1 Immune Checkpoint Inhibitors

Checkpoint inhibitors block proteins that prevent immune cells from attacking cancer,

showing success in melanoma, lung, and other cancers (Pardoll, 2012).

5.4.2 CAR-T Cell Therapy

Chimeric antigen receptor (CAR) T-cell therapy involves genetically engineering a patient's T cells to target cancer cells, a breakthrough in hematological malignancies (June et al., 2018).

5.5 Hormone Therapy

Hormone therapy is used in hormone-sensitive cancers, such as breast and prostate cancers, to block or reduce hormone production (Harris et al., 2009).

5.6 Supportive Care

Supportive care addresses symptoms and side effects of cancer treatment, including pain management, nutritional support, and psychological counseling (Hui et al., 2015).

5.7 Challenges and Future Directions

Cancer treatment faces challenges such as resistance, toxicity, cost, and access disparities. Innovations in personalized medicine, combination therapies, and novel drug development offer promising avenues for improving outcomes (Schilsky, 2014).

6. Prevention and Control of Cancer

6.1 Primary Prevention

Primary prevention aims to prevent the occurrence of cancer by addressing risk factors and promoting healthy behaviors.

6.1.1 Tobacco Control

Tobacco control through taxation, advertising restrictions, and smoking cessation programs has been effective in reducing smoking rates and related cancers (Jha et al., 2013).

6.1.2 Vaccination

Vaccination against oncogenic viruses such as HPV and Hepatitis B can prevent related cancers, such as cervical and liver cancers (Schiller et al., 2012).

6.1.3 Dietary and Lifestyle Interventions

Promoting a healthy diet, physical activity, and weight management can reduce the risk of several cancers, including colorectal and breast cancers (Colditz et al., 2016).

6.2 Secondary Prevention

Secondary prevention focuses on early detection and intervention to prevent cancer progression.

6.2.1 Screening Programs

Organized screening programs for breast, cervical, and colorectal cancers have been shown to reduce mortality through early detection (Myers et al., 2015).

6.2.2 Genetic Counseling and Testing

Genetic counseling and testing for high-risk individuals, such as those with BRCA mutations, can guide preventive interventions like prophylactic surgery (Domchek et al., 2010).

6.3 Tertiary Prevention

Tertiary prevention aims to reduce the impact of cancer through rehabilitation, survivorship care, and palliative care.

6.3.1 Rehabilitation

Rehabilitation programs address physical, emotional, and social challenges faced by cancer survivors, enhancing quality of life (Silver et al., 2015).

6.3.2 Survivorship Care

Survivorship care plans provide ongoing monitoring and support for long-term effects and secondary cancers (Mayer et al., 2015).

6.3.3 Palliative Care

Palliative care focuses on symptom management, psychosocial support, and end-of-life care, improving patient and family well-being (Temel et al., 2010).

6.4 Health Policy and Systems

Effective cancer prevention and control require coordinated health policies, resource allocation, and healthcare system strengthening.

6.4.1 Cancer Control Plans

National cancer control plans provide a strategic framework for comprehensive cancer care, including prevention, early detection, treatment, and research (World Health Organization, 2018).

6.4.2 Health Equity

Addressing disparities in access to prevention, screening, and treatment services is essential for equitable cancer outcomes (Sankaranarayanan et al., 2014).

6.4.3 Global Collaboration

International collaboration and partnerships are vital for sharing knowledge, resources, and best practices in cancer control (Trimble et al., 2017).

7. References

1. Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. *Cell, 144*(5), 646-674.
2. Stratton, M. R., Campbell, P. J., & Futreal, P. A. (2009). The cancer genome. Nature, 458(7239), 719-724.
3. Vogelstein, B., et al. (2013). Cancer genome landscapes. Science, 339(6127), 1546-1558.
4. Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011). Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science, 331(6024), 1565-1570.
5. Valastyan, S., & Weinberg, R. A. (2011). Tumor metastasis: molecular insights and evolving paradigms. Cell, 147(2), 275-292.
6. Fletcher, C. D. M. (2013). Diagnostic Histopathology of Tumors. Elsevier Health Sciences.
7. Garraway, L. A., & Lander, E. S. (2013). Lessons from the cancer genome. Cell, 153(1), 17-37.
8. Weinberg, R. A. (2013). *The Biology of Cancer*. Garland Science.
9. Fulda, S., & Debatin, K. M. (2006). Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. *Oncogene, 25*(34), 4798-4811.
10. Carmeliet, P., & Jain, R. K. (2011). Molecular mechanisms and clinical applications of angiogenesis. *Nature, 473*(7347), 298-307.
11. Valastyan, S., & Weinberg, R. A. (2011). Tumor metastasis: molecular insights and evolving paradigms. *Cell, 147*(2), 275-292.
12. American Cancer Society. (2021). *Cancer Facts & Figures 2021*. Atlanta: American Cancer Society.
13. Fletcher, C. D., et al. (2013). *WHO Classification of Tumours of Soft Tissue and Bone*. IARC Press.
14. Armitage, J. O., & Weisenburger, D. D. (1998). New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. *Journal of Clinical Oncology, 16*(8), 2780-2795.
15. Swerdlow, S. H., et al. (2016). *WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues*. IARC Press.

16. Louis, D. N., et al. (2016). The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. *Acta Neuropathologica*, *131*(6), 803-820.

17. Perou, C. M., et al. (2000). Molecular portraits of human breast tumours. *Nature*, *406*(6797), 747-752.

18. Edge, S. B., et al. (2010). *AJCC Cancer Staging Manual*. Springer.

19. Sung, H., et al. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209-249.

20. Miller, K. D., et al. (2019). Cancer treatment and survivorship statistics, 2019. CA: A Cancer Journal for Clinicians, 69(5), 363-385.

21. Bray, F., et al. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 types of cancer in 185 countries. CA: A Cancer Journal for Clinicians, 68(6), 394-424.

22. Farmer, P., et al. (2010). Expansion of cancer care and control in countries of low and middle income: a call to action. The Lancet, 376(9747), 1186-1193.

23. Wild, C. P., et al. (2020). Cancer prevention in the era of precision oncology. Nature Reviews Cancer, 20(9), 525-532.

24. Siegel, R. L., et al. (2020). Cancer statistics, 2020. CA: A Cancer Journal for Clinicians, 70(1), 7-30.

25. King, M. C., et al. (2003). Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science, 302(5645), 643-646.

26. Anand, P., et al. (2008). Cancer is a preventable disease that requires major lifestyle changes. Pharmaceutical Research, 25(9), 2097-2116.

27. Colditz, G. A., & Wei, E. K. (2012). Preventability of cancer: the relative contributions of biologic and social and physical environmental determinants of cancer mortality. Annual Review of Public Health, 33, 137-156.

28. Myers, E. R., et al. (2015). Benefits and harms of breast cancer screening: A systematic review. JAMA, 314(15), 1615-1634.

29. DeSantis, C. E., et al. (2019). Cancer statistics for African Americans, 2019. CA: A Cancer Journal for Clinicians, 69(3), 211-233.

30. King, M. C., et al. (2003). Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science, 302(5645), 643-646.

31. Stratton, M. R., et al. (2009). The cancer genome. Nature, 458(7239), 719-724.

32. Vogelstein, B., & Kinzler, K. W. (2004). Cancer genes and the pathways they control. Nature Medicine, 10(8), 789-799.

33. Doll, R., & Peto, R. (1981). The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. Journal of the National Cancer Institute, 66(6), 1191-1308.

34. Armstrong, B. K., & Kricker, A. (2001). The epidemiology of UV induced skin cancer. Journal of Photochemistry and Photobiology B: Biology, 63(1-3), 8-18.

35. Driscoll, T., et al. (2005). Occupational carcinogens: assessing the environmental burden of disease at national and local levels. Environmental Burden of Disease Series, No. 6. World Health Organization.

36. World Cancer Research Fund. (2018). Diet, Nutrition, Physical Activity and Cancer: A Global Perspective. World Cancer Research Fund International.

37. Friedenreich, C. M., et al. (2016). Physical activity and cancer outcomes: a precision medicine approach. Clinical Cancer Research, 22(19), 4766-4775.

38. Bagnardi, V., et al. (2015). Alcohol consumption and site-specific cancer risk: a comprehensive dose-response meta-analysis. British Journal of Cancer, 112(3), 580-593.

39. Bosch, F. X., et al. (2008). Comprehensive control of human papillomavirus infections and related diseases. Vaccine, 31, H1-H31.

40. El-Serag, H. B. (2012). Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology, 142(6), 1264-1273.e1.

41. Uemura, N., et al. (2001). Helicobacter pylori infection and the development of gastric cancer. New England Journal of Medicine, 345(11), 784-789.

42. Berwick, M., et al. (2006). Sun exposure and melanoma survival: a GEM study.

Cancer Epidemiology, Biomarkers & Prevention, 23(10), 2145-2152.

43. Barton, M. B., et al. (2014). Clinical practice guidelines for the psychosocial care of adults with cancer. Psycho-Oncology, 13(3), 159-173.

44. Hricak, H., et al. (2010). Imaging and imaging-based management of pelvic cancer: part I. Radiology, 254(3), 625-641.

45. Duffy, M. J. (2001). Tumor markers in clinical practice: A review focusing on common solid cancers. Medical Principles and Practice, 11(1), 22-30.

46. Oberman, H. A. (1998). Diagnostic histopathology of cancer. Archives of Pathology & Laboratory Medicine, 122(12), 1101-1102.

47. Tabár, L., et al. (2011). Swedish two-county trial: impact of mammographic screening on breast cancer mortality during 3 decades. Radiology, 260(3), 658-663.

48. Winawer, S. J., et al. (1993). Prevention of colorectal cancer by colonoscopic polypectomy. New England Journal of Medicine, 329(27), 1977-1981.

49. Saslow, D., et al. (2012). American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA: A Cancer Journal for Clinicians, 62(3), 147-172.

50. Moyer, V. A. (2012). Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Annals of Internal Medicine, 157(2), 120-134.

51. Pepe, M. S., et al. (2001). Phases of biomarker development for early detection of cancer. Journal of the National Cancer Institute, 93(14), 1054-1061.

52. Welch, H. G., & Black, W. C. (2010). Overdiagnosis in cancer. Journal of the National Cancer Institute, 102(9), 605-613.

53. Soneji, S., et al. (2014). Racial and ethnic disparities in early-stage lung cancer survival. Chest, 146(3), 724-735.

54. Gigerenzer, G., et al. (2010). Helping doctors and patients make sense of health statistics. Psychological Science in the Public Interest, 8(2), 53-96.

55. van der Wal, B. C. H., et al. (2015). Outcome of colorectal cancer surgery in

selected elderly patients. Medical Oncology, 32(1), 395.

56. Mercadante, S., et al. (2013). Palliative surgery in cancer patients. Supportive Care in Cancer, 21(5), 1419-1423.

57. Suda, K., et al. (2015). Robotic surgery for colorectal cancer. Annals of Gastroenterological Surgery, 3(2), 85-92.

58. Baskar, R., et al. (2012). Cancer and radiation therapy: current advances and future directions. International Journal of Medical Sciences, 9(3), 193-199.

59. Hoskin, P., et al. (2014). High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial. Radiotherapy and Oncology, 110(1), 39-45.

60. Choudhury, A., et al. (2016). Clinical Radiosensitizers for the Treatment of Rectal Cancer: A Systematic Review. Clinical Colorectal Cancer, 15(1), 1-12.

61. Chabner, B. A., & Roberts, T. G. (2005). Timeline: Chemotherapy and the war on cancer. Nature Reviews Cancer, 5(1), 65-72.

62. Sawyers, C. (2004). Targeted cancer therapy. Nature, 432(7015), 294-297.

63. Kaufmann, M., et al. (2007). Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. Journal of Clinical Oncology, 25(12), 1505-1515.

64. Pardoll, D. M. (2012). The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews Cancer, 12(4), 252-264.

65. June, C. H., et al. (2018). CAR-T cell immunotherapy for human cancer. Science, 359(6382), 1361-1365.

66. Harris, J. R., et al. (2009). Diseases of the Breast. Lippincott Williams & Wilkins.

67. Hui, D., et al. (2015). Integration of oncology and palliative care: a systematic review. The Oncologist, 20(1), 77-83.

68. Schilsky, R. L. (2014). Personalizing cancer care: American Society of Clinical Oncology presidential address 2009. Journal of Clinical Oncology, 27(23), 3725-3730.

69. Jha, P., et al. (2013). 21st-century hazards of smoking and benefits of cessation in the

United States. New England Journal of Medicine, 368(4), 341-350.

70. Schiller, J. T., et al. (2012). HPV vaccination: the promise & problems. Immunological Reviews, 239(1), 27-44.

71. Colditz, G. A., et al. (2016). Harvard report on cancer prevention volume 7: factors that contribute to cancer prevention. Cancer Causes & Control, 27(1), 1-6.

72. Myers, E. R., et al. (2015). Benefits and harms of breast cancer screening: a systematic review. JAMA, 314(15), 1615-1634.

73. Domchek, S. M., et al. (2010). Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA, 304(9), 967-975.

74. Silver, J. K., et al. (2015). Cancer rehabilitation and palliative care: critical components in the delivery of high-quality oncology services. Supportive Care in Cancer, 23(12), 3633-3643.

75. Mayer, D. K., et al. (2015). American Society of Clinical Oncology clinical expert statement on cancer survivorship care planning. Journal of Oncology Practice, 11(5), 388-395.

76. Temel, J. S., et al. (2010). Early palliative care for patients with metastatic non-small-cell lung cancer. New England Journal of Medicine, 363(8), 733-742.

77. World Health Organization. (2018). Cancer control: knowledge into action: WHO guide for effective programmes. World Health Organization.

78. Sankaranarayanan, R., et al. (2014). Cancer prevention and control in the context of an integrated approach. The Lancet, 390(10094), 492-534.

79. Trimble, E. L., et al. (2017). Global health in oncology: the new frontier. Bulletin of the World Health Organization, 95(7), 447-447.